MAY 2002
WEEK ENDING MAY 4
PRODUCT PC SPES, Prostate Formula, Herbal Dietary
Supplement, 60 capsules, 320 mg each, over-the-counter sales. Indicated for
"prostate health" claim. An herbal dietary supplement containing
Chinese herbs (Reishi, Baikal Skullcap, Rabdosia, Dyer's Woad, Mum, Saw
Palmetto, San- Qi Ginseng, Licorice).
CODE All lots and all codes.
RECALLING FIRM/MANUFACTURER International Medical
Research, dba Botanic Labs Inc., Brea, CA
REASON The product contains the undeclared prescription
drug; Warfarin
VOLUME OF PRODUCT IN COMMERCE Unknown.
DISTRIBUTION Nationwide and Internationally.
PRODUCT Cromolyn Sodium Nasal Solution USP, Each spray
delivers 5.2 mg cromolyn sodium,(40 mg/mL), 13 mL (100 sprays) and 26 mL (200
sprays) plastic spray pumps containers, Manufactured by Alpharma USPD under the
following labels:
Alpharma
Cromolyn Sodium Nasal Solution USP
Pfizer
BenaMist
Major
Cromolyn Sodium Nasal Solution USP
Perfect
Choice Cromolyn Sodium Nasal Solution USP
Kroger
Cromolyn Sodium Nasal Solution USP
Rite
Aid Cromolyn Sodium Nasal Solution USP
Walgreens
Wal-Crom
Longs
Nasal Allergy Symptom Controller
Eckerd
Cromolyn Sodium Nasal Solution USP
Equate
Cromolyn Sodium Nasal Solution USP
Good
Neighbor Cromolyn Sodium Nasal Solution USP
Leader
Nasal Allergy Control Spray
Savon/Osco
Cromolyn Sodium Nasal Solution USP
Valu-Rite
Nasal Allergy Symptom Controller
CVS
Cromolyn Sodium Nasal Solution USP
Family
Pharmacy Nasal Allergy Symptom Controller
Quality
Choice Cromolyn Sodium Nasal Solution USP
AAFES
Nasal Allergy Symptom Controller
Discount
Drug Mart Cromolyn Sodium Nasal Solution USP
CODE
Lot
Number Expiry Date
RA1009 31-Jul-02
RA1010 31-Aug-03
RB1068 31-Jul-03
RB1069 31-Jul-03
RB1069 31-Aug-03
RC1136 30-Sep-03
RC1191 30-Sep-03
RC1192 30-Sep-03
RC1193 31-Oct-03
RC1194 31-Oct-03
RH1442 31-Oct-03
RH1444 31-Oct-03
RH1445 31-Oct-03
RH1447 30-Nov-03
RH1448 30-Nov-03
RH1449 30-Nov-03
RH1450 30-Nov-03
RH1451 30-Nov-03
RH1452 30-Nov-03
RH1453 31-Dec-03
RH1454 31-Dec-03
RH1455 31-Dec-03
RH1456 31-Dec-03
RH1457 31-Dec-03
RH1458 31-Dec-03
RH1459 31-Jan-04
RH1460 31-Jan-04
RH1461 31-Jan-04
RH1462 31-Jan-04
RH1463 31-Oct-03
RH1464 31-Oct-03
RH1465 31-Dec-03
RH1466 31-Oct-03
RH1467 31-Oct-03
RH1468 30-Nov-03
RH1469 31-Dec-03
RS0847 31-Jul-03.
RECALLING FIRM/MANUFACTURER Alpharma USPD, Baltimore, MD
REASON Good Manufacturing Practice Deviations (CGMP):
Product was manufactured under the same conditions that yielded contaminated
(microbial)
product.
VOLUME OF PRODUCT IN COMMERCE 1,423,008 units.
DISTRIBUTION Nationwide.
PRODUCT Ranitidine Tablets, USP, 150 mg, Rx only, Unit-Dose
Tablets.
CODE Lot #4513-2002, Exp Date 7/31/02.
RECALLING FIRM/MANUFACTURER NCS HealthCare of KY; d.b.a.
Vangard Labs, Inc., Glasgow, KY
REASON Product name is mis-spelled on the outer carton
label.
VOLUME OF PRODUCT IN COMMERCE 1,056 cartons.
DISTRIBUTION Nationwide.
PRODUCT Lovastatin Tablets, USP, 20mg, bottle of 60 tablets,
Rx Only.
CODE Lots 220F11, Exp. 6/03 221F11, Exp. 6/03.
RECALLING FIRM/MANUFACTURER Purepac Pharmaceuticals,
Elizabeth, NJ
REASON Product failed stability requirement for impurity
level.
VOLUME OF PRODUCT IN COMMERCE Lot 220F11 -- 826,080
tablets as 13,768/60 count bottles; Lot 221F11 -- 848,820 tablets as 14,147/60
count bottles.
DISTRIBUTION Nationwide.
PRODUCT Urimax tablets in 100 count bottles and 2 tablets
patient sample package, Rx
Each
tablet contains:
Methenamine
81.60 mg
Sodium
Biphosphate 40.80 mg
Phenyl
salicylate 36.20 mg
Methylene
Blue 10.80 mg
Hyoscyamine
Sulfate 0.12 mg
CODE Lots 01101, 10202, 10309, 10406, 10502, 108012,
109001 and 110083.
RECALLING FIRM/MANUFACTURER Integrity Pharmaceutical
Corp., Indianapolis, IN
REASON Subpotent for one ingredient (hyoscyamine) at
stabilty testing.
VOLUME OF PRODUCT IN COMMERCE 55,800 bottles.
DISTRIBUTION Nationwide.
WEEK
ENDING MAY 11
PRODUCT Junior Strength Motrin
Tablets, Grape Flavored, Chewables (Ibuprofen 100 mg) 24 tablets per
bottle.
CODE Lot EBM073 exp. 2/03.
RECALLING
FIRM/MANUFACTURER McNeil Consumer & Speciality Pharmaceuticals, Fort Washington, PA
REASON Tablet mix-up; product may
contain one or more Women's Tylenol Menstrual Relief Caplets.
VOLUME OF
PRODUCT IN COMMERCE 79968 bottles.
DISTRIBUTION
Nationwide.
PRODUCT Hydrochlorothiazide Tablets,
USP, 25 mg, 1000-count Bottles.
CODE Lot no. 101607A, Exp. date
10/04.
RECALLING
FIRM/MANUFACTURER Recalling Firm: Ivax
Pharmaceuticals, Inc., Miami, FL
Manufacturer: Ivax Pharmaceuticals Caribe, Inc., Cidra,
Puerto Rico.
REASON Tablet mixup with
Hydrochlorothiazide 50mg and/or Acyclovir 400 mg tablets.
VOLUME OF
PRODUCT IN COMMERCE 17,117 bottles.
DISTRIBUTION
Nationwide.
PRODUCT Cortizone 5 and Cortizone
Kids Creme, (hydrocortisone) 0.5%, Anti-Itch Creme, 0.5, 0.65, 1, 1.3 and 2
ounce tubes, over-the-counter.
CODE All lots within expiry.
RECALLING
FIRM/MANUFACTURER Recalling Firm: Pfizer Consumer
Healthcare, Morris Plains, NJ
Manufacturer: Pfizer Inc., Parsippany, NJ
REASON Subpotent for Hydrocortisone
ingredient (stability).
VOLUME OF
PRODUCT IN COMMERCE 2,181,859 tubes
DISTRIBUTION
Nationwide
and Puerto Rico.
PRODUCT Triamcinolone Acetonide
Lotion, USP, 0.1%, Rx only, 60 mL plastic bottles.
CODE
Lot Expiration Date
M 405 4/02
M 441 5/02
M 480 6/02
M 504 7/02
M 546 8/02
M 615 10/02
M 623 12/02
M 697 1/03
M 716 2/03
M 749 2/03
M 812 3/03
M 846 5/03
M 911 6/03
M 931 6/03
M 948 7/03
N 002 8/03
N 070 10/03
N 088 11/03
N 136 12/03
N 685 4/03
N 754 4/03
N 796 5/03
N 230 2/04
N 302 4/04
N 330 5/04
N 423 8/04
N 424 8/04
N 480 9/04
N 499 12/04
N 545 11/04
N 617 1/05
N 651 3/05
N 862 7/05
N 873 7/05
N 874 7/05
N 906 8/05
N 949 10/05
P 017 12/05
P 018 12/05
P 026 12/05
Thames
Qualitest
Rugby, Prod. No. 602-2362
Schein
Goldline
Watson
RECALLING
FIRM/MANUFACTURER Thames Pharmacal Co., Inc., Ronkonkoma, NY
REASON Subpotent (stability).
VOLUME OF
PRODUCT IN COMMERCE 402,037 x 60 mL bottles total.
DISTRIBUTION
Nationwide
and Puerto Rico.
PRODUCT a) Levothyroxine Sodium
tablets, USP, 25 mcg. (0.025 mg) 100 and 1000 tablet bottles, Rx only, under
the Qualitest, Vintage
and URL label.
b) Q-Tuss Tablets, Sustained
Release, Rx only, 100 and 500 tablet bottles and bulk drums under the Qualitest
and Vintage label.
Each sustained release tablet contains:
Phenylephrine HCl
25 mg
Phenylpropanolamine HCl
50 mg
Chlorpheniramine Maleate
8 mg
Hyoscyamine Sulfate
0.19 mg
Atropine Sulfate
0.04 mg
Scopolamine Hydrobromide
0.01 mg
c) Chlordiazepoxide
Hydrochloride and Clidinium Bromide Capsules
(5 mg/2.5 mg) Rx only, 1000 tablet bottles under the
Qualitest and Vintage label
CODE a) Levothyroxine 0.025 mg.
002129C, 002129D, 002129E
b) Q-Tuss Tablets 039029A,
039029B, 039029C, 039029D, 138039B, 138039C, 142079A, 142079B
c) CDP/Clidinium Bromide
Tablets 034128A, 034128B.
RECALLING
FIRM/MANUFACTURER Vintage Pharmaceuticals, Inc., Charlotte, NC
REASON Stability; Potency data does
not support labeled expiration date.
VOLUME OF
PRODUCT IN COMMERCE a) 4,177 bottles Levothyroxine Sodium; b) 21,796 bottles and 495,222
tablets Q-Tuss;
c) 2,693 bottles
CDP/Clidinium Bromide.
DISTRIBUTION
AL.
PRODUCT a) Colchicine Tablets, USP,
0.6 mg, Rx only, 100 and 1000 tablet bottles under the Qualitest label.
b) Phenazopyridine
Hydrochloride Tablets, USP, 200 mg, Rx Only, 100 and 1000 tablet bottles under
the Qualitest and Vintage label.
CODE a) 055090A, 055090B,
112070A, 113070A; b) 045070A, 045070B, 045070C.
RECALLING
FIRM/MANUFACTURER Vintage Pharmaceuticals, Inc., Charlotte, NC
REASON Unapproved deviations in
manufacturing process (CGMP's).
VOLUME OF
PRODUCT IN COMMERCE a) 23,096 bottles; b) 8,599 bottles.
DISTRIBUTION
AL.
Maxair Inhaler Recalled
3M Pharmaceuticals Division today announced a
voluntary recall of the prescription medication Maxair Inhaler (pirbuterol
acetate inhalation aerosol). This is a press-and-breathe metered-dose inhaler.
The lot numbers are 000644, 000756, 000947, 001009, 001110, 001111, 010025,
010195, 010283, 010413, 010414, 010482, 010580, 010708, 010709, 011210. The
recall has been issued as a precaution to address the remote possibility that a
Maxair press-and-breathe aerosol inhaler may stick intermittently and patients
may not receive the expected puff of medication. This recall does not affect
Maxair Autohaler (pirbuterol acetate inhalation aerosol), a breath-actuated
metered-dose inhaler.
Patients currently using the Maxair
press-and-breathe inhaler are advised to return the product to their pharmacy.
3M is unable to offer patients an exact replacement unit at this time, as the
Maxair press-and-breathe inhaler is currently unavailable. Patients can obtain
the same medication in a different delivery device. 3M will provide Maxair
autohaler (pirbuterol acetate inhalation aerosol), a breath-actuated inhaler
(200 mcg pirbuterol/ inhalation), free of charge in exchange for the Maxair
press-and-breathe inhaler (200 mcg pirbuterol/inhalation). A physician
prescription will be required to obtain a Maxair autohaler or any other inhaler
replacement. The recall is being conducted with the knowledge of the U. S. Food
and Drug Administration.
3M Pharmaceuticals has provided a dedicated
toll-free number to respond to questions from patients and physicians. The
toll-free number is 1-800-390-1132. This line is available seven days a week,
8:30 a.m. to 5 p.m. EDT.
WEEK
ENDING MAY 18
PRODUCT Recall Extension for the
following products:a) Pangestyme Capsules (ETHEX brand) UL20 Pancrelipase
Enteric Coated Microtablets Contained in a Capsule, each capsule contains
20,000 USP units lipase, 65,000 USP units amylase, and 65,000 USP units
protease, packaged in 100-capsule bottles, RX only;
b) Pangestyme Capsules
(Ethex brand) MT16 Pancrelipase Enteric Coated Microtablets Contained in a
Capsule, each capsule contains 16,000 USP units lipase, 48,000 USP units
amylase and 48,000 USP units protease, packaged in 100-capsule bottles, , RX
only;
c. Pangestyme Capsules
(ETHEX brand) EC Pancrelipase Enteric Coated Microspheres Contained in
Capsules, each dye-free capsule contains 4,500 USP units lipase, 20,000 USP
units amylase, and 25,000 USP units protease, packaged in 12-, 100-, and
250-capsule bottles, (12's), (100's) and (250's), RX only.
CODE
a) Pangestyme UL20
Lot 28642, Exp. 04/02
Lot 28643, Exp. 06/02
Lot 28653, Exp. 06/02
Lot 29930, Exp. 06/02
Lot 29931, Exp. 06/02
Lot 29932, Exp. 06/02
Recall extension lot: Lot 34846, Exp 02/03
b) Pangestyme MT16
Lot 27478, Exp. 03/02
Lot 27479, Exp. 03/02
Lot 27480, Exp. 03/02
Lot 28639, Exp. 04/02
Lot 28640, Exp. 04/02
Lot 28641, Exp. 05/02
Lot 30245, Exp. 04/02
Recall extension lot: Lot 35703, Exp. 03/03
c) Pangestyme EC
Lot 27487, Exp. 05/02
Lot 27488, Exp. 05/02
Lot 27489 (250-ct.), Exp. 05/02
Lot 27777, Exp. 06/02
Lot 27778, Exp. 07/02
Lot 27779 (250-ct.), Exp. 07/02
Lot 27780 (250-ct.), Exp. 08/02
Lot 30882, Exp. 07/02
Lot 30883, Exp. 07/02
Lot 30934, Exp. 07/02
Recall extension lots:
Lot 30884, Exp 12/02
Lot 31558, Exp 12/02
Lot 32562, Exp 01/03
Lot 34399, Exp 01/03
Lot 34796, Exp 01/03
Lot 34835, Exp 03/03
Lot 35986, Exp 04/03
Lot 35987, Exp 04/03
Lot 36499, Exp 05/03.
RECALLING
FIRM/MANUFACTURER Recalling Firm: ETHEX Corp., St. Louis, MO
Manufacturer: KV Pharmaceutical Co., St. Louis, MO.
REASON Subpotency (Stability).
VOLUME OF
PRODUCT IN COMMERCE UL12 - 4,581 btls; UL18 - 3,474 btls; MT16 - 10,899 btls; UL20 - 8,728
btls; EC - 50,070 btls.
DISTRIBUTION
Nationwide.
PRODUCT Bactroban Ointment, brand of
mupirocin, 2% Ointment, 22 gram tubes, Rx only, distributed under the
SmithKline Beecham
Pharmaceuticals,
Philadelphia, PA label.
CODE
Lot No. Exp. date:
50-1B25 11/30/2002
29-1B25 9/30/2002
62-1B25 11/30/2002
84-1B25 2/28/2003
94-1B25 3/31/2003
106-1B25 4/30/2003.
RECALLING
FIRM/MANUFACTURER Glaxo SB Pharmco Puerto Rico, Inc., Cidra, Puerto Rico
REASON Microbial Contamination;
presence of Pseudomona fluorescens, Burkholderia pickettii or Ralstonia
paucula.
VOLUME OF
PRODUCT IN COMMERCE 194, 580 units (Tubes 22 grams).
DISTRIBUTION
Nationwide.
PRODUCT a) Mivacron Injection
(mivacurium chloride), Equivalent to 20
mg/10 mL (2 mg/mL) mivacurium, 10 mL Single-dose Fliptop
Vial, Rx only;
b) Nimbex Injection
(cisatracurium besylate), Equivalent to 10mg/5mL (2 mg/mL) cisatracurium, 5 mL
Single-dose Vial, Rx only;
c) Nimbex Injection
(cisatracurium besylate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple-dose Vial, Rx
only.
CODE a) lot 0H2493, exp. 05/02;
b) lot 0E2030, exp. 12/01; c) lot 0E2033, exp. 01/02.
RECALLING
FIRM/MANUFACTURER Recalling Firm: Abbott
Laboratories, Inc., Hospital Products Division, Abbott Park, IL
Manufacturer: DSM Catalytica Pharmaceuticals, Inc.,
Greenville, NC.
REASON Lack of assurance of
sterility.
VOLUME OF
PRODUCT IN COMMERCE a) 107,360 vials; b) 52,610 - 5 ml vials; c) 102,690 - 10 ml vials.
DISTRIBUTION
Nationwide.
PRODUCT Diflucan (Fluconazole)
Injection, 200 mg (2mg/mL), Iso-Osmotic Sodium Chloride Diluent, 100 mL saline
bag, Viaflex Plus single
dose, sterile, nonpyrogenic,
Rx only, Roerig, a div of Pfizer brand.
CODE Lot no. PS109439 Exp. date
5/03
RECALLING
FIRM/MANUFACTURER: Recalling Firm: Pfizer, Inc., New York, NY
Manufacturer: Baxter Health Corp. Jayuya, PR.
REASON Lack of assurance of
sterility; the port tube may be leaking.
VOLUME OF
PRODUCT IN COMMERCE 17,243 units.
DISTRIBUTION
Nationwide.
GlaxoSmithKline Alerts Patients, Pharmacists and Physicians to Watch for Third-Party Tampering that Incorrectly Labels Ziagen® as Combivir®
GlaxoSmithKline announced
today that the company has received four reports of suspect bottles containing
60 tablets of Combivir® (lamivudine plus zidovudine) that actually contained
another medicine, Ziagen® (abacavir sulfate) Tablets. The company has
determined that counterfeit labels for Combivir® Tablets were placed on two
bottles of Ziagen® and labels on another two bottles are suspect. Both
medicines are used as part of combination regimens to treat HIV infection.
The incidents appear to be
isolated and limited in scope. No injuries or adverse reactions have been
reported. Company tests have shown no problems with the medicine itself.
GlaxoSmithKline and the U.S. Food and Drug Administration are both
investigating. The company also is contacting health-care providers and
pharmacists to alert them to the situation and is alerting patients to check
their medicine to be sure they have received the correct tablets.
Pharmacists, physicians and
patients should immediately examine the contents of each Combivir® bottle to
confirm they do not contain Ziagen® tablets. The two kinds of tablets are
easily distinguishable. Combivir® is a white capsule-shaped tablet engraved
with "GX FC3" on one side; the other side of the tablet is plain.
Ziagen® is a yellow capsule-shaped tablet engraved with "GX 623" on
one face; the other side is plain. The Combivir® label shows a color photo of
the tablet.
The risk to patients is
primarily due to the fact that approximately 5% of individuals who receive
abacavir sulfate in Ziagen® or Trizivir® (abacavir sulfate, lamivudine and
zidovudine) Tablets have developed a potentially life-threatening hypersensitivity
reaction. Symptoms generally resolve after discontinuing the medication,
however, patients who have had a hypersensitivity reaction to Ziagen® are
advised to never take the medication again. Patients taking Combivir® would not
have been advised about the hypersensitivity reaction and how to take Ziagen®
safely because Combivir® does not contain abacavir sulfate. Patients who have
had a hypersensitivity reaction to abacavir yet take Ziagen® or Trizivir® again
experience more severe symptoms within hours that may include life-threatening
hypotension (lowering of the blood pressure) and death. In addition, the
replacement of Combivir® which contains two antiviral drugs with Ziagen®, a
single antiviral, may decrease the effectiveness of a patient's treatment
regimen. Patients should always confirm they have the right medication; for
patients taking Combivir® this is especially important now.
"While we cannot
determine the extent of counterfeit labeling, we believe this unfortunate
situation can be addressed by watchful pharmacists checking products before
dispensing them and careful patients double-checking their medications,"
said Peter Traber, senior vice president clinical development and medical
affairs at GSK. "Both patients and pharmacists can easily recognize the
difference between the two tablets and can identify if they have received the
wrong medicine before they take it." These steps should minimize the risk
to patients. Involved in the counterfeit labeling cases were 60-count bottles
of Combivir® Tablets, which contain 150-milligrams of lamivudine and 300
milligrams of zidovudine, and 60-count bottles of 300-milligram tablets of
Ziagen®.
Patients who have any question about their medicine should take it immediately to their pharmacist to have it checked. Pharmacists with questionable medicine should keep the bottle and report their concerns to GSK at 888-825-5249. Patients with questions should also call 888-825-5249.
Serono
Issues Notification of Counterfeit Serostim®
Serono, Inc. has recently
become aware of a counterfeit lot of Serono's Serostim® [somatropin
(rDNA origin) for injection]. The counterfeit material has been packaged to
appear as drug product lot number S810-1A1. This is not a legitimate Serostim®
lot number. Serono has notified the appropriate regulatory and law enforcement
authorities of this matter.
Preliminary information
appears to indicate that the counterfeit material may have been distributed via
the Internet. However, Serono is also alerting pharmacists to the counterfeit
material and recommending that they examine Serostim® prior to
dispensing to ensure that the package does not bear lot number S810-1A1. The
counterfeit material was neither manufactured nor distributed by Serono.
Therefore, it cannot be assumed that the counterfeit material is either safe or
effective.
Serono continues to
cooperate with regulatory and law enforcement authorities to identify and
prosecute individuals involved in drug counterfeiting. Serostim® is
approved in the U.S. for the treatment of AIDS wasting. Patients seeking
information regarding Serostim® may call Serono at 1-888-275-7376.
WEEK ENDING MAY 25
PRODUCT VERSED Syrup (midazolam HCl)
CIV, 118 ml (2mg/mL) bottles, Rx only.
CODE Lot U0009-50 exp. 4/2003 Lot
U0010-50 exp. 4/2003.
RECALLING
FIRM/MANUFACTURER Recalling Firm: Hoffmann La Roche Inc., Nutley, NJ
Manufacturer: Hoffmann-LaRoche,
Nutley, NJ.
REASON Potency, product
crystallization causing a lack of uniformity in potency.
VOLUME OF
PRODUCT IN COMMERCE 13,122 bottles.
DISTRIBUTION
Norway.
PRODUCT a) Endure 420 Cida-Stat Foam
(chlorhexidine gluconate) 2%, 27 oz (800 mL) bottles
b) Endure 420 Cida-Stat
Surgical Scrub/Healthcare Personnel Hand Wash (chlorhexidine gluconate) 2%, 4
oz, 18 oz and 1000 mL
bottles
c) Endure 400 Scrub-Stat 4
Surgical Scrub (chlorhexidine gluconate) 4%, 18 oz and 1000 mL bottles
d) Dial Surgical Scrub
(chlorhexidine gluconate) 4% Antimicrobial Solution, 4 oz and 1 gallon
bottles.
CODE a) Lots: L011291, L021291,
L041291, L092901 and L111601; b) Lot L091501; c) Lot L083191; d) Lot L083191;
RECALLING
FIRM/MANUFACTURER Ecolab Inc., Huntington, IN
REASON Subpotent for chlorhexidine
gluconate (stability).
VOLUME OF
PRODUCT IN COMMERCE 3700 cases/12-800 ml. bottles per case.
DISTRIBUTION
Nationwide.
PRODUCT a) 8.5% FreAmine III (Amino
Acid) Injection, 1000 mL glass intravenous infusion bottles, Rx only
b) 10% FreAmine III (Amino
Acid) Injection, 1000 mL glass intravenous infusion bottles, Rx only.
CODE Catalog Numbers S9030-SS and
S9010-SS Batch Numbers J2C029 and
J2C030.
RECALLING
FIRM/MANUFACTURER B. Braun Medical, Inc., Irvine, CA
REASON Packaging/ Labeling mix-up
(correctly labeled bottles of 8.5% FreAmine III were found in cartons
incorrectly labeled as 10% FreAmine III)
VOLUME OF
PRODUCT IN COMMERCE 11,478.
DISTRIBUTION
Nationwide.